Screening And Identification Of Peptide Specifically Combined With Gastric Cancer Cell SGC 7901

Objective:Use of in vivo Phage Display Technology to pan the short peptide specifically combined with gastric cancer tissue, in order to guide the early diagnosis and targeted therapy of the clinical gastric cancer, to enhance the direction of gastric cancer treatment.Method:To establish the nude mouse tumor model, inject the phage through the tail vein, pan four rounds, get enriched phage which binded to the short peptide, recycle and titer the phage of tumor tissue,heart tissue,Liver tissue and brain tissue,test it in the method of Immunohistochemistry and ELISA.Extracting phage DNA and sequencing it, specific short peptide sequences was obtained.RESULT:Nude mouse tumor model was successfully established. After four rounds of panning, Immunohistochemistry showed that the peptide binding to the tum-or tissue enriched significantly but the heart and Liver and brain tissue didn't.To titer the phage recovery,which binding to the tumor tissue is 88.8 times of the Liver tissue, 9.7×104 times of the heart tissue,6.7×104 times of the brain tissue. ELISA showed that of all the clones P/N>2.1 were 19, P/N>2.5 were 13.Among these P/N>3.0 were 3.Generally speaking,when the P/N (the clone of OD/the randomized controlled clone of OD)>2.1,it illustrated that this clone has a high affinity for SGC 7901. We obtained the peptide specifically binding to the phage and sequencing it successfully.CONCLUSION:Use of in vivo Phage Display Technology to pan the short peptide specifically combined with gastric cancer tissue.The peptide binding to the gastric tumor tissue enriched significantly after four rounds of panning. After sequence alignment, LLRSTGF occur most frequently.It suggests that this peptide may have a strong binging force to the nude mice model of gastric cancer and is expected to be-come a target for cancer therapy.